Oligonucleotide-based inhibitors comprising locked nucleic acid motif
The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.
1. An oligonucleotide comprising a sequence of 16 nucleotides, wherein the sequence is complementary to a miRNA and comprises no more than three contiguous locked nucleic acids (LNAs), wherein from the 5′ end to the 3′ end, positions 1, 5, 8, 10, and 16 of the sequence are LNAs, and wherein the miRNA is not miR-208a, miR-208b, or miR-499.
2. The oligonucleotide of claim 1 , wherein from the 5′ end to the 3′ end, the sequence further comprises LNAs at positions 6, 11, 13, and 15.
3. The oligonucleotide of claim 1 , wherein at least one of the non-locked nucleotides is 2′ deoxy, 2′ O-alkyl, or 2′ halo.
4. The oligonucleotide of claim 1 , wherein all of the non-locked nucleotides are 2′ deoxy.
5. The oligonucleotide of claim 1 , wherein at least one LNA has a 2′ to 4′ methylene bridge.
6. The oligonucleotide of claim 1 , wherein the oligonucleotide has a 5′ cap structure, 3′ cap structure, or 5′ and 3′ cap structure.
7. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises one or more phosphorothioate linkages.
8. The oligonucleotide of claim 7 , wherein the oligonucleotide is fully phosphorothioate-linked.
9. The oligonucleotide of claim 1 , further comprising a pendent lipophilic or hydrophilic group.
10. The oligonucleotide of claim 1 , wherein the miRNA is expressed in cardiac tissue.
11. The oligonucleotide of claim 1 , wherein the miRNA is miR-15a, miR-15b, miR-16-1, miR-16-2, miR-24, miR-25, miR-26a, miR-497, miR-195, miR-424, a let 7 family member, miR-21, miR-199a-b, miR-214, miR-10a-b, miR-16, miR-125b, miR-146a-b, miR-221, miR-222, a miR-30 family member, miR-126, miR-133, miR-1, miR-143, miR-145, miR-486, miR-92a, miR-320, miR-1-1, miR-1-2, miR-451, miR-378, miR-378*, miR-92, miR-34a, miR-34b, miR-34c, miR-29, or miR-33.
12. A pharmaceutical composition comprising an effective amount of the oligonucleotide of claim 1 , or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier or diluent.
13. The pharmaceutical composition of claim 12 , wherein the pharmaceutically-acceptable carrier comprises a colloidal dispersion system, macromolecular complex, nanocapsule, nanoparticle, microsphere, bead, oil-in-water emulsion, micelle, mixed micelle, or liposome.
14. The pharmaceutical composition of claim 12 , wherein the pharmaceutically-acceptable carrier or diluent consists essentially of saline.